Gliofocus: A Global, Open-Label, Randomized Phase 3 Study Comparing Niraparib with Temozolomide in Newly Diagnosed MGMT-Unmethylated Glioblastoma
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · e51
DOI: 10.1016/j.ijrobp.2026.06.765 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von W.R. Kennedy und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kennedy, W., Sanai, N., Mehta, S., Tien, A., Tovmasyan, A., Harmon, J., Chalmers, A., Khasraw, M., Lim-Fat, M., Minniti, G., Sepulveda, J., Touat, M., & Umemura, Y. (2026). Gliofocus: A Global, Open-Label, Randomized Phase 3 Study Comparing Niraparib with Temozolomide in Newly Diagnosed MGMT-Unmethylated Glioblastoma. International Journal of Radiation Oncology*Biology*Physics, 126(1), e51. https://doi.org/10.1016/j.ijrobp.2026.06.765
Vancouver
Kennedy W, Sanai N, Mehta S, Tien A, Tovmasyan A, Harmon J, et al. Gliofocus: A Global, Open-Label, Randomized Phase 3 Study Comparing Niraparib with Temozolomide in Newly Diagnosed MGMT-Unmethylated Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):e51. doi:10.1016/j.ijrobp.2026.06.765
BibTeX
@article{Kennedy2026,
author = {Kennedy, W.R. and Sanai, N. and Mehta, S. and Tien, A.C. and Tovmasyan, A. and Harmon, J. and Chalmers, A. and Khasraw, M. and Lim-Fat, M.J. and Minniti, G. and Sepulveda, J.M. and Touat, M. and Umemura, Y.},
title = {Gliofocus: A Global, Open-Label, Randomized Phase 3 Study Comparing Niraparib with Temozolomide in Newly Diagnosed MGMT-Unmethylated Glioblastoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {e51},
doi = {10.1016/j.ijrobp.2026.06.765}
}
EUVIMED